Buscar
01/05/2024
Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology
Caballero-Avila, M, Lleixà, C, Pascual-Goñi, E, Martín-Aguilar, L, Vidal-Fernandez, N, Tejada-Illa, C, Collet-Vidiella, R, Rojas-Garcia, R, Cortés-Vicente, E, Turon-Sans, J, Gallardo, E, Olivé, M, Vesperinas, A, Carbayo, A, Llansó, L, Martinez-Martinez, L, Shock, A, Christodoulou, L, Dizier, B, Freeth, J, Soden, J, Dawson, S, Querol, L. Membrane Proteome-Wide Screening of Autoantibodies in CIDP Using Human Cell Microarray Technology. Neurology-Neuroimmunology & Neuroinflammation. 2024; 11(3)DOI:10.1212/NXI.0000000000200216. PMID:38484217. IF:7.500(Q1/1D).
30/04/2024
Arterial pseudoaneurysm: a rare complication following laser lithotripsy-case series and literature review
Corrales, M, Hasan, MN, Carioti, GE, Emiliani, E, Doizi, S, Traxer, O. Arterial pseudoaneurysm: a rare complication following laser lithotripsy-case series and literature review. WORLD JOURNAL OF UROLOGY. 2024; 42(1)DOI:10.1007/s00345-024-04980-9. PMID:38693433. IF:2.900(Q2/3D).
26/04/2024
Long-lasting symptoms in borderline personality disorder: Defining an emergent population with differential clinical and therapeutic features
Casellas-Pujol, E, Soler, J, Schmidt, C, Soriano, J, Pascual, JC. Long-lasting symptoms in borderline personality disorder: Defining an emergent population with differential clinical and therapeutic features. Personality and Mental Health. 2024; 18(3)DOI:10.1002/pmh.1614. PMID:38666509. IF:2.700(Q2/4D).
25/04/2024
How appropriate is treating patients diagnosed with advanced esophageal cancer with anticancer drugs? A multicenter retrospective cohort Spanish study
Santero, M, Requeijo, C, Quintana, MJ, Rodríguez, D, Bottaro, D, Macias, I, Pericay, C, Farina, N, Blanco, JM, Urreta-Barallobre, I, Punti, L, Nava, MA, Cosp, XB. How appropriate is treating patients diagnosed with advanced esophageal cancer with anticancer drugs? A multicenter retrospective cohort Spanish study. Clinical & Translational Oncology. 2024; 26(10)DOI:10.1007/s12094-024-03436-1. PMID:38662169. IF:2.500(Q3/6D).
24/04/2024
First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug
Pieren, M, Gutiérrez-Solana, AA, Arbós, RMA, Boyle, GW, Davila, M, Davy, M, Gitzinger, M, Husband, L, Martínez-Martínez, MS, Mazarro, DO, Pefani, E, Penman, SL, Remuiñán, MJ, Vlasakakis, G, Zeitlinger, M, Dale, GE. First-in-human study of alpibectir (BVL-GSK098), a novel potent anti-TB drug. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY. 2024; 79(6)DOI:10.1093/jac/dkae107. PMID:38656557. IF:3.600(Q2/3D).
24/04/2024
An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis treated with ixekizumab from 26 clinical studies
Schwartzman, S, Puig, L, Cohen, AD, Khattri, S, Jossart, C, Diaz, C, Garrelts, A, Zhu, DT, Eberhart, N, Eleftheriadi, A, Tangsirisap, N, Schuster, C, Gottlieb, AB, Sheesh, M. An integrated safety analysis of treatment-emergent fungal infections in patients with psoriasis, psoriatic arthritis, or axial spondyloarthritis treated with ixekizumab from 26 clinical studies. RHEUMATOLOGY. 2024; 63DOI:10.1093/rheumatology/keae163.211. PMID:. IF:4.400(Q1/1D).